There are several treatment options available for spinal muscular atrophy (SMA), a rare genetic condition characterized by progressive muscle weakness and wasting. The disease mainly affects motor ...
The next level to watch is the 100-day Simple Moving Average (SMA) at 0.6425, followed by the weekly top at 0.6549 (November 25), and finally the 200-day SMA at 0.6553. On the downside ...
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
Evrysdi is the only non-invasive disease-modifying treatment for SMA. The 5 mg Evrysdi tablet can either be swallowed whole or dispersed in water. “Evrysdi has robust potential to modify the SMA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback